Zheng Yu-huang, He Yan, Yang Xu, Gong Guo-zhong, Zhou Hua-ying, Zhang Chun-ying, Zhou Wen, Huang Li, Ding Pei-pei, Li Hui
AIDS Research Laboratory, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Zhonghua Gan Zang Bing Za Zhi. 2005 Oct;13(10):741-4.
To evaluate the clinical effect and side-effect of interferon-alpha (IFN-a) and ribavirin (RBV) combination therapy for Chinese patients with co-infection of hepatitis C virus (HCV) and human immunodeficiency virus (HIV), and to compare them with only HIV infection patients.
10 patients with HCV-HIV and 17 patients with only HCV infection received 5 million units of IFNalpha-2b every other day intramuscularly, and 300 mg RBV orally three times a day. Dynamic observations were done for HCV RNA and HIV RNA loads, CD4+ and CD8+ T lymphocyte counts, liver function and blood cell measures, and the side-effects of the medicines.
After 12 weeks and 24 weeks of IFNalpha and RBV combination therapy, mean HCV RNA levels reduced 1.14 log (t = 3.843, P < 0.01) and 2.08 log (t =6.564, P < 0.01) from the baseline at week 0 in the HCV-HIV co-infection group, and reduced 1.48 log (t = 6.438, P less than 0.01) and 2.33 log (t = 7.343, P < 0.01) in the HCV infection group. Meanwhile, the HIV RNA levels decreased 1.22 log (t = 3.662, P < 0.01) and 1.73 log (t = 6.119, P < 0.01) from the base line. However, there were no obvious different changes among T lymphocyte counts of HCV-HIV and HCV patients at week 0, week 12 and week 24. All 27 patients showed satisfactory biochemical response to therapy. There were some mild or moderate influenza-like symptoms, intestinal discomfort and decreased blood cell counts in the early stages of the treatments. No neuropsychic and auto-immune disorders were found.
IFNalpha-2b and RBV combination therapy showed similar anti-HCV effects during the 24 week treatment for HCV-HIV and HCV infected patients, and some anti-HIV effect was also observed. No obvious different biochemical responses and side-effects were found between the above two groups.
评估干扰素-α（IFN-α）联合利巴韦林（RBV）治疗丙型肝炎病毒（HCV）和人类免疫缺陷病毒（HIV）合并感染的中国患者的临床疗效和副作用，并与仅感染HIV的患者进行比较。
10例HCV-HIV合并感染患者和17例仅感染HCV的患者，隔日肌肉注射500万单位的IFNα-2b，每日口服300mg RBV，分三次服用。对HCV RNA和HIV RNA载量、CD4+和CD8+ T淋巴细胞计数、肝功能和血细胞指标以及药物副作用进行动态观察。
在HCV-HIV合并感染组，IFNα和RBV联合治疗12周和24周后，平均HCV RNA水平较0周基线分别降低1.14对数（t = 3.843，P < 0.01）和2.08对数（t = 6.564，P < 0.01）；在HCV感染组，分别降低1.48对数（t = 6.438，P < 0.01）和2.33对数（t = 7.343，P < 0.01）。同时，HIV RNA水平较基线分别降低1.22对数（t = 3.662，P < 0.01）和1.73对数（t = 6.119，P < 0.01）。然而，在0周、12周和24周时，HCV-HIV合并感染患者和HCV患者的T淋巴细胞计数没有明显差异。所有27例患者对治疗均表现出满意的生化反应。治疗早期出现一些轻度或中度的流感样症状、肠道不适和血细胞计数下降，但未发现神经精神和自身免疫性疾病。
在对HCV-HIV合并感染患者和HCV感染患者进行的24周治疗中，IFNα-2b联合RBV治疗显示出相似的抗HCV效果，同时也观察到一定的抗HIV效果。上述两组之间未发现明显不同的生化反应和副作用。
